Table 1.

Patient characteristics (n = 178)

	CPLN negative		CPLN positive (≥5 mm)		P value a
	Median	IQR	Median	IQR
Age (y)	64.70	50.15‐73.54	63.48	51.42‐71.42	.872
FIGO stage
IIIA/IIIB	16	18.0	2	2.2
IIIC	62	69.7	11	12.4
IVA	11	12.3	2	2.2
IVB	0	0	74	83.2	.0001
Histologic subtype
High‐grade serous	69	77.5	73	82.0
Low‐grade serous	12	13.5	3	3.4
Mucinous	1	1.1	2	2.2
Endometrioid	5	5.6	8	9.0
Clear cell	2	2.3	3	3.4	.205
Grading
G1	13	14.7	4	4.5
G2	43	48.3	39	43.8
G3	33	37.0	46	51.7	.029
Debulking surgery
Yes	89	100	89	100
No	0	0	0	0
Residual disease
No residual disease	80	89.9	53	59.6
Residual disease	9	10.1	36	40.4	.0001
Lymphadenectomy b
Systematic (≥20 nodes)	79	88.8	71	79.8
Sampling (<20 nodes)	2	2.2	6	6.7	.199
Adjuvant chemotherapy
Carboplatin + paclitaxel	77	86.5	73	82.0
Carboplatin	11	12.4	13	14.6
Cisplatin + endoxan	1	1.1	3	3.4	.529
Platinum response c
Refractory + resistant	14	15.7	21	23.6
Sensitive	75	84.3	68	76.4	.403
Recurrence
Yes	42	47.2	77	86.5
No	47	52.8	12	13.5	.0001
Death
Yes	27	30.3	53	59.6
No	62	69.7	36	40.4	.0001

Values are expressed as median, IQR for ‘Age’ and as n, % for all other characteristics.

Abbreviations: CPLN, cardiophrenic lymph node; FIGO, Fédération Internationale de Gynécologie Obstétrique; IQR, interquartile range.

^aDifferences assessed by Mann‐Whitney U test (Age) or chi‐square test.

^bSystematic retroperitoneal lymphadenectomy. ¹²

^cPlatinum sensitivity according to The Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. ¹³